IGF2BP1 and gastric cancer: Unlike most m6A modification regulators, ALKBH5 (Suo et al., 2024[228]; Hu et al., 2022[83]; Wang et al., 2024[261]), IGF2BP1 (Xu et al., 2022[305]; Ding et al., 2024[47]), and YTHDF2 (Ren et al., 2024[198]; Yang et al., 2022[314]; Shen et al., 2020[210]) exhibit both oncogenic and anti-oncogenic effects in gastric cancer.